# TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

> **NCT04954781** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 25 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Tislelizumab
- **COMBINATION_PRODUCT:** TACE

## Key facts

- **NCT ID:** NCT04954781
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-14
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954781, "TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04954781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*